World Journal of Gastroenterology - Baishideng Publishing Group

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 44

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3895)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-3) series.

Item

Count

PDF

WORD

HTML

2396

Figures (1-4)

307

Tables (1-3)

266

Sum=3075

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

187

Download

469

Sum=656

Nov 28, 2023 (publication date) through Feb 18, 2025

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Cited by in CrossRef

For:	Peng WT, Jiang C, Yang FL, Zhou NQ, Chen KY, Liu JQ, Peng SF, Fu L. Tenofovir amibufenamide vs tenofovir alafenamide for treating chronic hepatitis B: A real-world study. World J Gastroenterol 2023; 29(44): 5907-5918 [PMID: 38111506 DOI: 10.3748/wjg.v29.i44.5907]
URL:	https://www.wjgnet.com/1007-9327/full/v29/i44/5907.htm

Number	Citing Articles
1	Yongzheng Hu, Yue Zhang, Wei Jiang. Targeting hepatitis B virus-associated nephropathy: efficacy and challenges of current antiviral treatments. Clinical and Experimental Medicine 2025; 25(1) doi: 10.1007/s10238-025-01584-4
2	Qing Zhang, Jianhua Xu, Dan Liu, Lilin Wang, Shan Ren, Sujun Zheng, Xinyue Chen, Li Qi, Junfeng Lu. Comparative efficacy and safety of tenofovir amibufenamide vs tenofovir alafenamide in the initial 48-week treatment of high viral load chronic hepatitis B: A single-centre retrospective study. Antiviral Therapy 2024; 29(5) doi: 10.1177/13596535241284226
3	Xinxin Rong, Guangde Yang, Yuanyuan Xu, He Chen, Xia Wang, Juanjuan Fu, Li Li, Xiucheng Pan. Efficacy and Safety of Tenofovir Amibufenamide and Tenofovir Alafenamide for First‐Time HBV‐Related Decompensated Cirrhosis. Journal of Viral Hepatitis 2024; doi: 10.1111/jvh.14029
4	Ken Lin, Su-Wen Jiang, Ai-Rong Hu. Management of antiviral treatment for chronic hepatitis B patients with high viral load. World Chinese Journal of Digestology 2024; 32(9): 625 doi: 10.11569/wcjd.v32.i9.625 Abstract() \| Core Tip() \| Full Article(HTML)() \| Times Cited (0) \| Total Visits (0) \| Open
5	Chuang Jiang, Zhi-Hong Zhang, Jia-Xin Li. Current status of drug therapy for chronic hepatitis B. World Journal of Gastroenterology 2025; 31(2): 99443 doi: 10.3748/wjg.v31.i2.99443 Abstract(117) \| Core Tip(111) \| Full Article(HTML)(665) \| Full Article with Cover (PDF)-719K(24) \| Audio-727K(1) \| Peer-Review Report-175K(20) \| Answering Reviewers-256K(16) \| Full Article (PDF)-471K(78) \| Full Article (XML)-268K(20) \| Times Cited (0) \| Total Visits (1300) \| Open
6	Li-Yang Meng, Chao-Ting Yang, Jian-Feng Bao, Jin-Song Huang. Effectiveness and safety of tenofovir amibufenamide in chronic hepatitis B patients. World Journal of Gastroenterology 2024; 30(26): 3261-3263 doi: 10.3748/wjg.v30.i26.3261 Abstract(329) \| Core Tip(333) \| Full Article(HTML)(932) \| Full Article with Cover (PDF)-558K(46) \| Audio-434K(3) \| Peer-Review Report-197K(29) \| Answering Reviewers-54K(28) \| Full Article (PDF)-330K(91) \| Full Article (XML)-27K(36) \| Times Cited (1) \| Total Visits (2281) \| Open
7	Shenglong Lin, Wanlong Huang, Ziyuan Liao, Huaxi Ma, Wenjun Wu, Minghua Lin, Defu Huang, Haibing Gao. Comparison of lipid profile alterations in chronic hepatitis b patients receiving tenofovir alafenamide or tenofovir disoproxil fumarate. Scientific Reports 2024; 14(1) doi: 10.1038/s41598-024-78656-0